Andrew Strickland
About
Andrew Strickland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Andrew Strickland has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Andrew Strickland's work include Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Andrew Strickland is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Andrew Strickland collaborates with scholars based in Australia, United Kingdom and United States. Andrew Strickland's co-authors include Timothy Price, Andrés Cervantes, Marc Peeters, Cornelis J.A. Punt, Yevhen Hotko, Thierry André, Alberto Sobrero, Tudor–Eliade Ciuleanu, Laslo Roman and Michel Ducreux and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.
In The Last Decade
Andrew Strickland
28 papers receiving 1.1k citations
Hit Papers
Peers
Andrew Strickland
Roger Sidhu United States
Swantje Held Germany
Vicente Alonso-Orduña Spain
Clemens Gießen Germany
M. E. Vega-Villegas Spain
Claus-Christoph Steffens Germany
José María Viéitez Spain
Joe McKendrick Australia
Marie‐Pierre Galais France
Tadamichi Denda Japan
Citations per year, relative to Andrew Strickland Andrew Strickland (= 1×)
peers
Roger Sidhu
Countries citing papers authored by Andrew Strickland
Since
Specialization
Citations
This map shows the geographic impact of Andrew Strickland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Strickland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Strickland more than expected).
Fields of papers citing papers by Andrew Strickland
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrew Strickland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Strickland. The network helps show where Andrew Strickland may publish in the future.
Co-authorship network of co-authors of Andrew Strickland
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Strickland. A scholar is included among the top collaborators of Andrew Strickland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Strickland. Andrew Strickland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Evans, T.R. Jeffry, Andrew Strickland, Zev A. Wainberg, et al.. (2025). First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial. The Lancet Oncology. 27(1). 90–102.
2.
Sun, Jong‐Mu, Yee Chao, Sung‐Bae Kim, et al.. (2024). MORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC).. Journal of Clinical Oncology. 42(3_suppl). 324–324.
3.
Jiang, Di, Hao‐Wen Sim, Lillian L. Siu, et al.. (2023). Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer. 22(4). 457–463.
4.
Ciardiello, Fortunato, Yung‐Jue Bang, Andrés Cervantes, et al.. (2023). Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results. Cancer Medicine. 12(12). 13145–13154.
5.
Michael, Michael, Rachel Wong, Sanjeev Gill, et al.. (2023). The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.. Journal of Clinical Oncology. 41(16_suppl). 3616–3616.
6.
Lundy, Joanne, Andrew Strickland, Marion Harris, et al.. (2022). KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?. Cells. 11(19). 3175–3175.
7.
Elston, Marianne S., Dev Kevat, Richard Carroll, et al.. (2021). Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. Cancer Medicine. 10(23). 8405–8411.
8.
Ciardiello, Fortunato, Yung‐Jue Bang, Johanna C. Bendell, et al.. (2021). PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.. Journal of Clinical Oncology. 39(15_suppl). 3109–3109.
9.
Klein, Oliver, Damien Kee, Bo Gao, et al.. (2021). Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. Journal for ImmunoTherapy of Cancer. 9(11). e003156–e003156.
10.
Hughes, Daniel, et al.. (2018). Endoscopic Electrohydraulic Lithotripsy for Large Bowel Obstruction Secondary to Colonic Gallstone Impaction. ACG Case Reports Journal. 5(1). e33–e33.
11.
Tebbutt, Niall C., Timothy Price, Nicole Wong, et al.. (2016). Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer. 114(5). 505–509.
12.
Pavlakis, Nick, Katrin Marie Sjoquist, Andrew Martin, et al.. (2015). INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. Journal of Clinical Oncology. 33(3_suppl). 9–9.
13.
Bridgewater, John, Andrés Cervantes, Ben Markman, et al.. (2015). GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(3_suppl). 669–669.
14.
Peeters, Marc, Kelly S. Oliner, Timothy Price, et al.. (2014). Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 32(3_suppl). LBA387–LBA387.
15.
Ringash, Jolie, Heather‐Jane Au, Lillian L. Siu, et al.. (2013). Quality of life in patients with K‐RAS wild‐type colorectal cancer. Cancer. 120(2). 181–189.
16.
Tebbutt, Niall C., Timothy Price, Katrin Marie Sjoquist, et al.. (2013). Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer.. Journal of Clinical Oncology. 31(15_suppl). 4081–4081.
17.
Peeters, Marc, Timothy Price, Andrés Cervantes, et al.. (2010). Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 28(31). 4706–4713.
18.
Karapetis, Christos S., Desmond Yip, Andrew Strickland, et al.. (2010). A phase I and II trial of epirubicin, cisplatin, 24‐hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology. 6(4). 298–305.
19.
Strickland, Andrew, N. Beechey‐Newman, Christopher Steer, & Peter Harper. (2002). Sentinel node biopsy: an in depth appraisal. Critical Reviews in Oncology/Hematology. 44(1). 45–70.
20.
Provis, Chris & Andrew Strickland. (2000). South Australia: Caution and Consistency. Australian Journal of Public Administration. 59(4). 84–92.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Roger Sidhu Breakdown of academic impact, for papers by Swantje Held Breakdown of academic impact, for papers by Vicente Alonso-Orduña Breakdown of academic impact, for papers by Clemens Gießen Breakdown of academic impact, for papers by M. E. Vega-Villegas Breakdown of academic impact, for papers by Claus-Christoph Steffens Breakdown of academic impact, for papers by José María Viéitez Breakdown of academic impact, for papers by Joe McKendrick Breakdown of academic impact, for papers by Marie‐Pierre Galais Breakdown of academic impact, for papers by Tadamichi Denda